We investigated whether structural central neural damage and long-term neurobehavioral deficits after L-cysteine (L-Cys) administration in mice is caused by hypoglycemia. Neonatal ICR mice were injected subcutaneously with L-Cys (0.5-1.5 mg/g body weight [BW]) or saline (control). Blood glucose was measured. At 50 days of age, mice were introduced individually into an eight-arm maze for evaluation of spatial memory (hippocampal-related behavior). Times for visiting all eight arms and number of entries until completion of the eight-arm visits (maze criteria) were measured. The test was repeated once daily for 5 days. In situ terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay was used for detection of brain damage. As early as 20 min and up to 2 h postinjection, animals treated with L-Cys doses higher than 1.2 mg/g BW developed hypoglycemia and looked ill. Several animals convulsed. Long-term survivors required more time, in a dose-dependent manner, to assimilate the structure of the maze, and animals treated with L-Cys (1.5 mg/g BW) exhibited TUNEL-positive changes in the hippocampal regions. All these changes were reversible by coadministration of glucose. We conclude that L-Cys injection can cause pronounced hypoglycemia associated with long-term neurobehavioral changes and central neural damage in mice. Since L-Cys is chemically different from the other excitatory amino acids (glutamate and aspartate), the long-reported L-Cys-mediated neurotoxicity may be connected to its hypoglycemic effect.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0091-3057(03)00147-3 | DOI Listing |
Alzheimers Dement
December 2024
Afe Babalola University, Ado-Ekiti, Ekiti, Nigeria.
Background: Stress during pregnancy and postpartum periods has been associated with short-term cognitive deficits with potential long-term Alzheimer's disease (AD) risk. However, the biological mechanisms mediating these effects remain poorly understood. This study investigated the impacts of recurrent heat and simulated refugee camp stress across pregnancy and the postpartum period on cognition, affective behaviour, and AD neuropathological changes in primiparous rats.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Tulane University, New Orleans, LA, USA.
Background: Clinical studies indicate that mid-life dietary patterns are a risk factor for cognitive decline. Adherence to a Mediterranean diet (MeDi) may promote healthy brain aging in contrast to a Western diet (WD), yet these diets have not been examined in pre-clinical models. We hypothesized that consumption of the MeDi would have better cognitive performance compared to the Western diet in middle-aged rats.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Department of Pediatrics, Division of Infectious Diseases and Immunology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Background: Alzheimer's disease (AD) is a progressive irreversible dementia characterized by beta-amyloid protein plaque deposition and hyperphosphorylation of tau forming neurofibrillary tangles, and neurodegeneration. An emerging theory posits that infections could be one of the triggering factors in AD development and progression. Multiple lines of evidence have linked Chlamydia pneumoniae (Cp), a gram-negative obligate intracellular bacterium with AD.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
The Framingham Heart Study, Framingham, MA, USA.
Background: The long-term neurological impact of the SARS-CoV-2 virus is unknown and it remains to be seen whether it would create a surge in cases of dementia and cognitive decline years later, which is already a global public health challenge. Our group has previously shown that participants cognitive functioning as measured via mobile-based assessments using smartphone-based cognitive tests did not differ based on their COVID status. The goal of the present study was to examine participants longitudinal cognitive performance with the hypothesis that participants with a previous COVID-19 diagnosis (COVID+) will have worse cognitive performance over time than those without COVID-19 (COVID-).
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Centre for Healthy Brain Ageing (CHeBA), University of New South Wales, UNSW Sydney, NSW, Australia.
Background: Subjective cognitive complaints (SCCs) and neuropsychiatric symptoms (NPS) are emerging as potential early indicators of neurodegenerative diseases like Alzheimer's disease (AD). SCCs refers to a self-perceived decline in cognitive abilities without objective impairment, while NPS describe neuropsychiatric symptoms that emerge in later life that may precede or co-occur with cognitive decline. This study explores the association between SCCs, NPS, global cognition, and incident dementia using data from the Sydney Memory and Ageing Study (MAS).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!